Literature DB >> 26371818

Reply: Further Progress in Understanding Fibrosing Mediastinitis.

Tobias Peikert1, Blair Westerly1, Ulrich Specks1.   

Abstract

Entities:  

Year:  2015        PMID： 26371818      PMCID： PMC4595682          DOI： 10.1164/rccm.201506-1183LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

1.  Rituximab for IgG4-related disease: a prospective, open-label trial.

Authors:  Mollie N Carruthers; Mark D Topazian; Arezou Khosroshahi; Thomas E Witzig; Zachary S Wallace; Philip A Hart; Vikram Deshpande; Thomas C Smyrk; Suresh Chari; John H Stone
Journal:  Ann Rheum Dis       Date:  2015-02-09       Impact factor: 19.103

Review 2.  IgG4-related disease.

Authors:  Terumi Kamisawa; Yoh Zen; Shiv Pillai; John H Stone
Journal:  Lancet       Date:  2014-12-04       Impact factor: 79.321

3.  Targeting B lymphocytes in progressive fibrosing mediastinitis.

Authors:  Blair D Westerly; Geoffrey B Johnson; Fabien Maldonado; James P Utz; Ulrich Specks; Tobias Peikert
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

4.  Histopathologic Overlap between Fibrosing Mediastinitis and IgG4-Related Disease.

Authors:  Tobias Peikert; Bijayee Shrestha; Marie Christine Aubry; Thomas V Colby; Jay H Ryu; Hiroshi Sekiguchi; Thomas C Smyrk; Ulrich Specks; Eunhee S Yi
Journal:  Int J Rheumatol       Date:  2012-05-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.